Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Conditions: Leukemia; Acute Lymphoblastic Leukemia

Interventions: Drug: CD22CART infusion; Drug: Tisagenlecleucel

Sponsors: Stanford University

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 13, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments